Equities analysts predict that Clovis Oncology (NASDAQ:CLVS) will post earnings per share of ($1.73) for the current quarter, according to Zacks Investment Research. Five analysts have issued estimates for Clovis Oncology’s earnings, with the highest EPS estimate coming in at ($1.57) and the lowest estimate coming in at ($1.84). Clovis Oncology reported earnings of ($1.27) per share during the same quarter last year, which suggests a negative year-over-year growth rate of 36.2%. The firm is scheduled to issue its next earnings results on Monday, February 25th.

On average, analysts expect that Clovis Oncology will report full year earnings of ($6.80) per share for the current financial year, with EPS estimates ranging from ($7.02) to ($6.50). For the next fiscal year, analysts forecast that the company will post earnings of ($5.55) per share, with EPS estimates ranging from ($6.93) to ($4.84). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that follow Clovis Oncology.

Clovis Oncology (NASDAQ:CLVS) last released its quarterly earnings data on Tuesday, October 30th. The biopharmaceutical company reported ($1.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.60) by ($0.11). Clovis Oncology had a negative net margin of 390.65% and a negative return on equity of 108.92%. The business had revenue of $22.76 million during the quarter, compared to analysts’ expectations of $30.11 million. During the same quarter in the prior year, the firm posted ($1.24) earnings per share. The firm’s quarterly revenue was up 35.4% on a year-over-year basis.

A number of research analysts recently weighed in on CLVS shares. JPMorgan Chase & Co. reiterated a “buy” rating and issued a $71.00 price objective on shares of Clovis Oncology in a research note on Friday, September 21st. Guggenheim started coverage on shares of Clovis Oncology in a research note on Monday, September 17th. They issued a “buy” rating for the company. SunTrust Banks lowered shares of Clovis Oncology to a “buy” rating and lifted their price objective for the company from $20.00 to $70.00 in a research note on Wednesday, October 31st. Oppenheimer reiterated a “hold” rating on shares of Clovis Oncology in a research note on Tuesday, October 30th. Finally, Piper Jaffray Companies started coverage on shares of Clovis Oncology in a research note on Thursday, October 18th. They issued a “hold” rating and a $33.00 price objective for the company. Three investment analysts have rated the stock with a sell rating, four have assigned a hold rating and ten have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $56.32.

A number of large investors have recently made changes to their positions in CLVS. Bank of Montreal Can boosted its holdings in Clovis Oncology by 2,420.9% in the 2nd quarter. Bank of Montreal Can now owns 15,831 shares of the biopharmaceutical company’s stock valued at $720,000 after purchasing an additional 15,203 shares during the period. Amalgamated Bank boosted its holdings in Clovis Oncology by 23.9% in the 2nd quarter. Amalgamated Bank now owns 7,283 shares of the biopharmaceutical company’s stock valued at $331,000 after purchasing an additional 1,406 shares during the period. Los Angeles Capital Management & Equity Research Inc. boosted its holdings in Clovis Oncology by 39.1% in the 2nd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 49,849 shares of the biopharmaceutical company’s stock valued at $2,267,000 after purchasing an additional 14,025 shares during the period. Rice Hall James & Associates LLC boosted its holdings in Clovis Oncology by 4.1% in the 2nd quarter. Rice Hall James & Associates LLC now owns 154,115 shares of the biopharmaceutical company’s stock valued at $7,008,000 after purchasing an additional 6,036 shares during the period. Finally, NJ State Employees Deferred Compensation Plan boosted its holdings in Clovis Oncology by 18.2% in the 2nd quarter. NJ State Employees Deferred Compensation Plan now owns 13,000 shares of the biopharmaceutical company’s stock valued at $591,000 after purchasing an additional 2,000 shares during the period.

Clovis Oncology stock opened at $21.24 on Wednesday. Clovis Oncology has a 1-year low of $11.50 and a 1-year high of $69.02. The company has a debt-to-equity ratio of 2.46, a current ratio of 9.03 and a quick ratio of 8.46.

Clovis Oncology Company Profile

Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.

See Also: What is a Market Correction?

Get a free copy of the Zacks research report on Clovis Oncology (CLVS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Clovis Oncology (NASDAQ:CLVS)

Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.